ZIO-202

ZIO-202 is a small molecule DNA alkylating agent that was developed by Alaunos Therapeutics (formerly Ziopharm Oncology) as a second-generation analogue of isophosphoramide mustard (IPM). Chemically identified as N-2-bromoethyl-N'-2-mesyloxyethylphosphorodiamidic acid, it was designed as a back-up candidate to palifosfamide (ZIO-201) to provide enhanced stability and anti-tumor activity. The molecule functions by forming covalent cross-links with DNA, which disrupts DNA replication and transcription, leading to cell cycle arrest and apoptosis. Preclinical studies demonstrated its efficacy in various human cancer xenograft models, including ovarian, pancreatic, and prostate cancers. Although it showed potential in early research, development of ZIO-202 did not progress into clinical trials as the developer shifted its focus toward TCR-T cell therapies and other immuno-oncology platforms.

Other names

N-2-bromoethyl-N'-2-mesyloxyethylphosphorodiamidic acid